###begin article-title 0
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 550 566 550 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2, ATM, ESR1</italic>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFN</italic>
###xml 573 579 573 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
###xml 594 598 594 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 613 616 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 618 635 618 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1, MLH1, RARB</italic>
###xml 640 647 640 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD17B4</italic>
###xml 800 803 800 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 1119 1120 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1258 1259 1258 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1347 1350 1347 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 1563 1566 1563 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 387 392 <span type="species:ncbi:9606">women</span>
###xml 961 969 <span type="species:ncbi:9606">patients</span>
###xml 1396 1404 <span type="species:ncbi:9606">patients</span>
Bilaterality of breast cancer is an indicator of constitutional cancer susceptibility; however, the molecular causes underlying this predisposition in the majority of cases is not known. We hypothesize that epigenetic misregulation of cancer-related genes could partially account for this predisposition. We have performed methylation microarray analysis of peripheral blood DNA from 14 women with bilateral breast cancer compared with 14 unaffected matched controls throughout 17 candidate breast cancer susceptibility genes including BRCA1, BRCA2, CHEK2, ATM, ESR1, SFN, CDKN2A, TP53, GSTP1, CDH1, CDH13, HIC1, PGR, SFRP1, MLH1, RARB and HSD17B4. We show that the majority of methylation variability is associated with intragenic repetitive elements. Detailed validation of the tiled region around ATM was performed by bisulphite modification and pyrosequencing of the same samples and in a second set of peripheral blood DNA from 190 bilateral breast cancer patients compared with 190 controls. We show significant hypermethylation of one intragenic repetitive element in breast cancer cases compared with controls (P = 0.0017), with the highest quartile of methylation associated with a 3-fold increased risk of breast cancer (OR 3.20, 95% CI 1.78-5.86, P = 0.000083). Increased methylation of this locus is associated with lower steady-state ATM mRNA level and correlates with age of cancer patients but not controls, suggesting a combined age-phenotype-related association. This research demonstrates the potential for gene-body epigenetic misregulation of ATM and other cancer-related genes in peripheral blood DNA that may be useful as a novel marker to estimate breast cancer risk.
###end p 2
###begin p 3
Accession numbers: The microarray data and associated .BED and .WIG files can be accessed through Gene Expression Omnibus accession number: GSE14603.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C1">1</xref>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 233 236 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 295 296 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C2">2</xref>
###xml 676 677 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C3">3</xref>
###xml 1112 1113 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C4">4</xref>
###xml 1114 1115 1102 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C5">5</xref>
###xml 1370 1371 1358 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C6">6</xref>
###xml 89 94 <span type="species:ncbi:9606">women</span>
###xml 1631 1639 <span type="species:ncbi:9606">patients</span>
Breast cancer is one of the most common cancers in the Western world affecting one in 10 women during their lifetime (1). Mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, and, to a lesser extent, CHEK2, TP53 and ATM, account for approximately25% of familial breast tumours (2). The remaining 75% of familial breast cancers (BRCAx tumours) and the majority of sporadic tumours are not attributable to known mutations in any of these genes. In bilateral cases of breast cancer (a second primary tumour in the contra-lateral breast), it is believed that the underlying 'mutation' is not limited to the epithelial cells of one breast, but rather is systemic (3). The importance of epigenetic changes in cancer development is now well established; however, the role of epigenetic changes as a mechanism for increased cancer risk is yet to be fully explored. Therefore, we hypothesized that some of the systemic epigenetic changes are either inherited or acquired in the early developmental stages and therefore should be detectable in the tissues other than breast, such as peripheral blood DNA (4,5). Since carcinogenesis induces numerous genetic and epigenetic changes, the study of tumour cells alone cannot distinguish whether epigenetic inactivation of tumour suppressor genes is a cause or a consequence of the neoplastic process in breast cancer (6). Identification of epimutations in the tissues and cells that are not affected by the disease process would favour causal association. Therefore, we aimed to identify epigenetic misregulation of candidate genes in the normal peripheral blood cells of cancer patients compared with controls.
###end p 5
###begin p 6
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C7">7</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C8">8</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C9">9</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C10">10</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C11">11</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C12">12</xref>
###xml 1486 1488 1486 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C13">13</xref>
###xml 688 692 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 793 799 <span type="species:ncbi:9606">humans</span>
Epigenetics is the investigation of 'any information that is carried by the genome that is not coded by DNA' and includes DNA methylation, histone modifications, chromatin structure and non-coding RNA-mediated regulation of gene expression and various other genomic functions (7). DNA methylation studies in cancer revealed two main types of changes: hypermethylation of promoter CpG islands and hypomethylation of repetitive DNA sequences (8). DNA methylation is heritable through mitosis and is copied to the new strand by DNA methylatransferase 1 during DNA replication. Meiotic heritability of DNA methylation states, particularly transposon-associated methylation, has been shown in mice and in plants; however, it is not yet clear whether DNA methylation is heritable through meiosis in humans (9,10). Recent evidence suggests that epimutations are likely to arise somatically (11). Apart from trans-generational inheritance of epigenetic states, single-generation germline epigenetic effects are also possible. During germ cell development, the epigenome is reprogrammed with two waves of demethylation and re-establishment of DNA methylation marks allowing the possibility of errors that could persist in the germline (12). We have previously shown that the male germline exhibits locus-, cell- and age-dependent DNA methylation differences and that DNA methylation variation is significant across unrelated individuals, at a level that, by far, exceeds DNA sequence variation (13). This has allowed us to hypothesize that epigenetic variation in normal somatic cells, which need not be transgenerational, could be a predisposing factor for cancer.
###end p 6
###begin p 7
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C14">14</xref>
###xml 383 414 383 414 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://matrix.ugent.be/pubmeth/">http://matrix.ugent.be/pubmeth/</uri>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 595 618 595 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2, ATM, CHEK2, TP53</italic>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 699 702 699 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFN</italic>
###xml 704 710 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
###xml 719 723 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 738 741 738 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 743 760 743 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1, MLH1, RARB</italic>
###xml 765 772 765 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD17B4</italic>
DNA methylation alterations have been studied extensively in breast tumour tissues most recently with genome wide analyses revealing hypermethylated as well as hypomethylated loci compared with matched adjacent tissues (14). Approximately 100 candidate genes have been reported throughout the literature as promoters hypermethylated at varying frequencies in breast cancers (Pubmeth http://matrix.ugent.be/pubmeth/search.html). For our study, we have selected genes that have either previously been identified as breast cancer susceptibility genes with known mutations in familial cases (BRCA1, BRCA2, ATM, CHEK2, TP53) or genes that are frequently hypermethylated in sporadic breast cancers (ESR1, SFN, CDKN2A, GSTP1, CDH1, CDH13, HIC1, PGR, SFRP1, MLH1, RARB and HSD17B4). We have used a two-stage design to firstly identify methylation variable positions (MVPs) in peripheral blood DNA and then secondly to test selected sites for an association with breast cancer in a larger sample set.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
Microarray analysis
###end title 9
###begin p 10
###xml 547 548 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 837 840 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 842 845 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 847 851 847 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 860 865 860 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 867 871 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 873 877 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RARB</italic>
###xml 879 886 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD17B4</italic>
###xml 888 892 888 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 894 899 894 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 904 910 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1041 1046 1041 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1048 1053 1048 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1055 1059 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1061 1064 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFN</italic>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 1075 1080 1075 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
We performed differential DNA methylation analysis using a methylation-sensitive enzyme-based approach to compare the methylation status of peripheral blood DNA of 14 bilateral breast cancer cases with 14 matched controls. We have designed a custom-tiled microarray covering a total of 4 Mb to completely cover 17 breast cancer susceptibility genes () and an additional 34 genes also captured in the flanking regions (). Using the Model-based Analysis of 2-Color Arrays (MA2C) algorithm, we were able to detect 181 significantly variable regions (P < 0.001) across the 28 individuals, which we have termed inter-individual MVPs. These included 143 intragenic, or gene-body, MVPs and 38 intergenic regions not associated with known gene promoters (). We observed intragenic methylation variability in each of the remaining targeted genes ATM, PGR, CDH1, CDH13, CHEK2, MLH1, RARB, HSD17B4, ESR1, SFRP1 and CDKN2A. Of all of the genes tested, we detected no significant intragenic methylation variability in six of the targeted genes including BRCA1, BRCA2, TP53, SFN, HIC1 and GSTP1 ().
###end p 10
###begin title 11
Methylation variability is located in intragenic repetitive elements
###end title 11
###begin p 12
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F1">1</xref>
###xml 1314 1315 1314 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F1">1</xref>
Although the repetitive sequences themselves are not tiled, the enrichment of unmethylated genome can assess methylation status of the repetitive sequences by probing the unique sequences flanking the repeats (gaps in the tiling microarrays) (). To confirm the association of MVPs with repetitive elements, we have calculated the distance from the middle of each peak to the nearest repetitive element for each of the 181 identified loci. This analysis identified 80/181 (44%) of MVPs within 100 bp of the nearest repetitive element and 60% within 200 bp. This distribution is significantly closer to repetitive elements than can be expected by random chance (P = 7.39e-07, Kolmogorov-Smirnov test) (Fig. 1A). The distribution of repeat element type is not significantly different to the distribution throughout the genome. By aligning each gene at the transcription start sites (TSSs) and averaging the MATScores, we were able to generate a general picture of methylation variability over the first 10 kb of genes longer than 10 kb or across the first 5 kb of shorter genes. This reveals very low methylation variability over all gene promoters up to the TSS and a sharp increase in variability over the first 1 kb of intragenic sequence followed by periodic increase and decrease in variability every 2 kb (Fig. 1B).
###end p 12
###begin p 13
###xml 101 102 101 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 537 538 537 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Methylation microarray analysis of 17 genes reveals methylation variability in repetitive elements. (A) The distance from each of the MVP to the nearest repetitive element was calculated for each of the 181 distinct MVPs revealing 44% of peaks within 100 bp of the nearest repetitive element. Random placement of 181 simulated MVP peaks reveals a distribution containing only 26% of peaks within 100 bp of the nearest repetitive element. Kolmogorov-Smirnov test was used to determine the significance of the difference in distribution. (B) The smoothed average of MATScores (+/-2 SD in red) for genes aligned at the TSS reveals periodic increase in methylation variability across the first 10 kb (of genes >10 kb) or across the first 5 kb (of shorter genes, median 4.5 kb).
###end p 13
###begin title 14
Investigation of DNA methylation of ATM
###end title 14
###begin p 15
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F2">2</xref>
###xml 504 507 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 836 837 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F2">2</xref>
###xml 1254 1258 1254 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPAT</italic>
###xml 1263 1266 1263 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 1287 1288 1287 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F2">2</xref>
###xml 1600 1603 1600 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
We have performed a detailed validation of the MVPs within the targeted region surrounding one gene, ATM, which we have selected because it is known to contain germline mutations in familial breast cancer cases with a clear pathogenic role and it contains several intragenic MVPs associated with repetitive elements (Fig. 2A). We used bisulphite modification coupled with pyrosequencing assays to map methylated cytosines in the repetitive elements nearest to six MVPs in the targeted region surrounding ATM. We first analysed the 14 matched case-control paired samples that we performed the microarray analysis on. Pair-wise comparison of methylation percentages confirmed the significant inter-individual variability in each of the loci identified by the microarray as exemplified by ATMmvp2a with 8/14 pairs significantly different (P < 0.05, Wilcoxon signed rank sum test) (Fig. 2B). Combined data from all of the 14 cases and controls revealed no statistically significant differences overall between patients and controls; however, the highest range of methylation across individuals were observed in the intragenic regions nearest the TSSs. The two most variable loci, ATMmvp1 and ATMmvp2, are both 4 kb downstream of the start sites of the genes NPAT and ATM, respectively (Fig. 2C). We detected no significant difference in genome-wide methylation as assessed by the pyrosequencing assay for LINE1; therefore, any differences detected are unlikely to be due to overall genome-wide methylation differences. Furthermore, in each of the 14 cases and controls, we detected no methylation of the ATM promoter CpG island in the peripheral blood DNA.
###end p 15
###begin p 16
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 79 82 79 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 267 268 267 268 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 654 655 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 742 745 742 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
Investigation of ATM gene methylation. (A) Methylation microarray data for the ATM gene locus. Seven methylation variable peaks were detected across the tiled region surrounding the ATM gene. Data are presented as a custom WIG file track on the UCSC genome browser. (B) Pair-wise comparison of ATM mvp2a methylation reveals increased methylation in 5/14 bilateral breast cancer patients (blue) compared with matched controls (yellow). Methylation of six CpG dinucleotides within the repetitive element mvp2a was determined by pyrosequencing. Pair-wise Wilcoxon signed rank sum test was used to determine statistical significance (# indicates P < 0.05). (C) DNA methylation analysis of MVPs reveals significant variability detected within the ATM gene. LINE 1 assay shows no significant differences in methylation of LINE1 repetitive elements in peripheral blood DNA of cases (blue) compared with controls (yellow). Methylation variability was detected in mvp1b, mvp2a, mvp2b, mvp3 and mvp4. Box and whisker plots represent median (centre line), inter-quartile range (box) and 95th percentiles (whisker), and samples outwith this range are represented as points.
###end p 16
###begin p 17
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F3">3</xref>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 735 736 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 933 934 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 950 953 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 953 954 951 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1067 1068 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1123 1124 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP033TB1">1</xref>
###xml 1421 1422 1419 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP033TB2">2</xref>
###xml 1831 1832 1829 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1985 1986 1983 1984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1998 1999 1996 1997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2042 2043 2040 2041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2053 2054 2051 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2086 2087 2084 2085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2097 2098 2095 2096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2134 2135 2132 2133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2145 2146 2143 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
###xml 1732 1740 <span type="species:ncbi:9606">patients</span>
###xml 1907 1915 <span type="species:ncbi:9606">patients</span>
We performed a second stage of validation for the most variable loci, MVP2, within the ATM gene as well as the ATM CpG island and LINE1 assays in peripheral blood DNA from 190 bilateral breast cancer patients compared with 190 controls (Fig. 3). Again, we detected no significant difference between cases and controls in the LINE1 assay or the ATM CpG island. The LINE1 assay did, however, show inter-individual variability with genome-wide methylation values ranging from the lowest individual at 48% to the highest at 74% (median 56%). We did detect a significant increase in methylation of ATMmvp2b in the bilateral breast cancer patients (range 72.8-98.4%, mean 91.4%) compared with control individuals (range 53-98%, mean 89.8%) (P = 0.001686, Wilcoxon rank sum test) (). We have used an inter-quartile analysis of the ATM mvp2b methylation data to reveal a significant increase in methylation in cases in the highest quartile (P = 0.0011 using chi2 test), which is associated with a 3-fold increased risk of breast cancer (odds ratio-OR 3.20, 95% CI 1.78-5.86, P = 0.000083), compared with the lowest quartile (Table 1). We have analysed these data to identify whether the methylation status of this locus is associated with any phenotypic characteristics. We have investigated the age at blood draw (median 6.6 years after second diagnosis), age at first and second diagnoses and the time between diagnoses (Table 2). There was no association between the methylation level and tumour morphology, age at first full-term pregnancy, age at menarche, menopausal status, body mass index, weight, parity and the number of affected first-degree relatives (data not shown). Only the age and the age of diagnoses in the breast cancer patients were significantly associated with the methylation status (adjusted for multiple testing, P = 0.01035). Interestingly, even though the controls were age-matched with patients, age was not correlated with the methylation status in the controls (r = -0.1077, P = 0.07), only in the cases at blood draw (r = 0.242, P = 0.0004), at first diagnosis (r = 0.189, P = 0.0045) and at second diagnosis (r = 0.251, P = 0.0002) ().
###end p 17
###begin p 18
###xml 120 121 120 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 253 254 253 254 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 833 834 833 834 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Methylation of LINE1, ATM CpG island, mvp2a and mvp2b in 190 bilateral breast cancer cases compared with 190 controls. (A) Schematic of the genomic location of the ATM CpG island (CGI) at the TSS and at mvp2a and mvp2b within the second intron of ATM. (B) Pyrosequencing-based methylation analysis of 190 bilateral breast cancer cases compared with 190 matched controls reveals no methylation in the promoter CpG island and significant inter-individual methylation variability in the intronic mvp2a and mvp2b. Significant hypermethylation of mvp2b is detected in bilateral breast cancer cases compared with controls (P = 0.0017, Wilcoxon signed rank sum test). Box and whisker plots represent median (centre line), inter-quartile range (box) and 95th percentiles (whisker), and samples outwith this range are represented as points. (C) Kernel density plot of methylation values in cases (solid line) compared with controls (dotted lines) showing overlapping distributions for LINE1, ATM CpG island and ATM mvp2a and a skewed distribution of methylation at ATM mvp2b in the cases.
###end p 18
###begin p 19
Inter-quartile analysis of ATM mvp2b methylation reveals increased risk of breast cancer in the highest quartile
###end p 19
###begin p 20
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Association between methylation of ATM mvp2b and phenotypic data from the bilateral breast cancer patients and controls reveals an association between methylation and age in cases but not in controls
###end p 20
###begin p 21
NA, not applicable.
###end p 21
###begin p 22
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
aLinear model regression.
###end p 22
###begin p 23
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
bFDR corrected for multiple testing.
###end p 23
###begin p 24
###xml 37 38 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
**Signifies significant association (P < 0.05).
###end p 24
###begin p 25
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C15">15</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
It is well defined that different tissues show differential methylation particularly between different peripheral blood cell types (CD4+ and CD8+ T cells compared with B cells) (15). Therefore, the small effect (increase in methylation at ATM mvp2b) in patients compared with controls could be due to a larger effect in a small subpopulation of cells within the heterogeneous peripheral blood cell population. We have addressed this question by isolation of B cells, T cells and monocytes from peripheral blood mononuclear cells (PBMCs) from two healthy controls and investigating the methylation status of this locus. We show that the methylation of ATMmvp2b does not show cell-specific methylation differences between these three blood cell fractions, and all fractions have similar methylation levels to the whole PBMCs ().
###end p 25
###begin p 26
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 388 389 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F4">4</xref>
###xml 474 477 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C16">16</xref>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP033F4">4</xref>
###xml 790 793 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
In order to investigate the relationship between methylation at ATM mvp2b and expression of ATM, we screened a large panel of cancer cell lines and observed a similar methylation range as seen in peripheral blood (77-99%); however, the distribution of methylation percentages is significantly higher in the cancer cell lines than in the peripheral blood DNA of the patients and controls (P < 1e-14, Wilcoxon signed rank test) (Fig. 4A). We performed quantitative RT-PCR for ATM expression in five breast cancer cell lines (MCF7, T47D, SKBR3, MDA-MB-231 and BT549) and analysed pre-existing gene expression data for 18 mesenchymal tumour cell lines (16) (Fig. 4B and C). In both cases, we observed a correlation between the methylation of the intragenic repetitive element and expression of ATM (Spearmans rho -0.9 and -0.33, respectively).
###end p 26
###begin p 27
###xml 90 91 90 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 431 432 431 432 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 552 553 552 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
Correlation between methylation of ATM mvp2b and expression of ATM in cancer cell lines. (A) Methylation analysis in 62 cancer cell lines reveals a similar range of methylation as in PBMCs of breast cancer patients (77-99%); however, the distribution is skewed towards increased methylation in the cancer cell lines (green). Methylation distributions of breast cancer patients (red) and controls (black) are shown for comparison. (B) ATM expression was determined by qRT-PCR in the five breast cancer cell lines and by gene expression microarray data (C) for a panel of sarcoma cell lines. Error bars represent SEM from triplicate qRT-PCR experiments. Correlation between methylation and expression is shown using Spearmans rank correlation coefficient.
###end p 27
###begin title 28
DISCUSSION
###end title 28
###begin p 29
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C17">17</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C18">18</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C19">19</xref>
###xml 1306 1308 1306 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C20">20</xref>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 570 577 <span type="species:ncbi:9606">patient</span>
This project is the first comprehensive DNA methylation study using high-density tiling arrays to look for methylation variation in white blood cells of bilateral breast cancer patients compared with controls. It is well established that identification of high-risk patients guiding the use of preventative treatment such as intensive surveillance (e.g. mammography), chemoprevention (e.g. tamoxifen) or prophylactic surgery (e.g. radical mastectomy) can significantly reduce the burden of breast cancer (17). Therefore, all additional tools with which we can predict a patient's risk of cancer, such as DNA methylation markers, would improve our ability to identify those at high risk. The difficulty in finding genetic markers of common breast cancer risk has been recently exemplified by a number of extraordinarily large case-control studies that have identified only minor increases in breast cancer risk (18,19). The overall goal of this current study was to screen candidate genes for epigenetic differences in peripheral blood DNA to identify markers of common breast cancer risk. We believe that DNA methylation markers could be more informative, as they are more stable than other candidate biomarkers such as RNA or protein-based markers, and can act as a surrogate for environmental exposures (20). The extent to which epigenetic markers can be used for risk assessment is yet to be fully explored.
###end p 29
###begin p 30
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C21">21</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C23">23</xref>
###xml 187 198 187 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Arabidopsis</italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C22">22</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C21">21</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C24">24</xref>
###xml 1529 1531 1529 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C22">22</xref>
###xml 895 900 <span type="species:ncbi:9606">human</span>
'Gene body methylation' is a recent term describing the DNA methylation that occurs throughout the gene from the TSS, through exons and introns, to the 3' untranslated region (21-23). In Arabidopsis, the level of gene-body methylation has been linked to the level of gene transcription such that gene-body methylation was absent in genes that were not transcribed, was low in genes that were transcribed at low levels, higher levels of methylation in the highest transcribed genes but even higher methylation levels in genes that had intermediate levels of transcription (22). Gene-body methylation is also more associated with genes on the active X chromosome rather than on the inactive X-chromosome (21). The association with the transcription of individual genes and gene-body methylation has not yet been investigated in cancer. We have recently suggested that gene-body methylation in the human genome may be associated with intragenic repetitive elements and that altered methylation in the gene-body may be a mechanism of modulating the level of transcription (24). In the present study, we show for the first time that the methylation of one intragenic repetitive element inversely correlates with the expression of the gene which supports this hypothesis. Although there are numerous examples in the literature showing that active genes have more gene-body methylation levels than inactive genes, all of these studies compare the gene body methylation levels of one gene with another and compare the expression levels (22). These studies make a distinction between 'On' expression and gene-body methylation compared with 'Off' expression and no gene-body methylation. We suggest from our data that the level of gene-body methylation may be modulating or fine-tuning the level of expression of the active genes. To date, there has been no report looking at the subtle differences in gene-body methylation across samples and associating that with the expression of the same gene in those samples. Therefore, our study is the first report of an association between different levels of gene-body methylation and expression of the same gene.
###end p 30
###begin p 31
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C22">22</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C25">25</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C26">26</xref>
How gene-body methylation may alter the gene expression, or alternatively how expression level may affect the methylation level, is still not clear. The mvp within ATM that we have identified could be a reporter of a more extended regulatory epigenetic profile at ATM, similar to a tag SNP for a region of linkage disequilibrium in DNA sequence variation. Alternatively, this region could be involved in the regulation of unannotated non-coding transcript(s) or antisense transcripts that regulate the sense gene (22). Recent reports have shown a high level of antisense transcription throughout the genome which could be involved in gene regulation, which suggests new levels of understanding of the process of transcriptional regulation (25,26).
###end p 31
###begin p 32
###xml 1305 1308 1293 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFN</italic>
###xml 1310 1315 1298 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
###xml 1320 1324 1308 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 1450 1455 1438 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1457 1462 1445 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1467 1471 1455 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1559 1564 1547 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 652 657 <span type="species:ncbi:9606">women</span>
Our study of the breast cancer susceptibility genes has provided evidence that the regions of inter-individual methylation variability are located within repetitive elements, particularly SINEs (Alu sequences), and that the variability is highest at approximately1 kb downstream of the TSSs and increases periodically along the gene. We interpret this increased variability as the point in the genome where the methylation along the chromatin is changing from unmethylated at the promoters to fully methylated in the gene-body. We have identified one repetitive element, ATM mvp2b, which is significantly more methylated in the peripheral blood DNA of women affected with bilateral breast cancer compared with matched control individuals. On its own, this is not sufficient to be considered a potential diagnostic test, as there is considerable overlap between cases and controls and the receiver operating curve area under the curve of 0.59 supports this lack of specificity as a diagnostic. However, this may improve in combination with similar markers from the other genes that we have identified, if such markers provide an additive effect. Interestingly, not all genes showed signs of inter-individual methylation variability. For some of the genes, this could be explained by the short length (e.g. SFN, GSTP1 and HIC1); however, this is not the case for other longer genes which could represent genes with conserved methylation patterns (e.g. BRCA1, BRCA2 and TP53) compared with other long genes that show high levels of methylation variability (e.g. CDH13).
###end p 32
###begin p 33
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C27">27</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C28">28</xref>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 340 343 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C29">29</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C32">32</xref>
###xml 593 596 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C31">31</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C34">34</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C35">35</xref>
###xml 1039 1042 1039 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
The ataxia telangiectasia (A-T) mutated (ATM) gene is considered a breast cancer susceptibility gene, as female heterozygotes from A-T families have an increased risk of breast cancer and a number of breast cancer families have been identified with germline ATM mutations (27,28). Although one small study by Vo et al. identified increased ATM promoter methylation associated with decreased expression in locally advanced sporadic breast cancers, numerous other reports suggest no evidence of promoter methylation of this gene in breast cancers (29-32). One finding that is consistent is that ATM expression is often reduced in breast tumours (31-34). This could be explained by genetic haploinsufficiency (35); however, our data in peripheral blood DNA and cancer cell lines suggest a novel mechanism of decreased expression mediated by aberrant gene-body methylation, which warrants further investigation in tumour tissues. We propose that if normal tissues of the individual, including mammary epithelial cells, express lower levels of ATM owing to aberrantly increased gene-body methylation, then these individuals may be more susceptible to DNA mutations in those cells.
###end p 33
###begin p 34
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C36">36</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C37">37</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C38">38</xref>
###xml 119 124 <span type="species:ncbi:9606">women</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
The biggest risk factor for breast cancer and indeed most cancers is increasing age. The incidence of breast cancer in women doubles for every 10 years until menopause with a relative risk of >10-fold (36). An association between DNA methylation and increasing age has also been reported, for example increased DNA methylation variability in older twins compared with younger twins and increasing variability with increasing age in familial clusters (37,38). However, we have found that the association between the level of methylation at ATM mvp2b and increasing age is only associated in the bilateral breast cancer patients and not in controls. This suggests that the relationship between age and DNA methylation may be more dependent on the phenotype of the individuals, in this case cancer, and may be due to other predisposing environmental exposures that accumulate with age.
###end p 34
###begin p 35
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
One of the confounding factors which we cannot rule out in this study is the long-term effects of previous therapy in the patients that are not present in the controls. Future studies will need to investigate peripheral blood samples taken before the initiation of treatment preferably in prospectively collected cohort studies to rule out this possibility. However, if therapy accounted for an overall difference in genome-wide DNA methylation, the LINE1 assay for genome-wide methylation and the other unique sites tested (ATM mvp2a) would have detected this, which it did not. Another confounding factor is the effect of tissue-specific methylation. Although we have shown that in two healthy controls there is no evidence for cell-type-specific methylation of this locus, we cannot rule out this possibility in cancer patients. Therefore, this needs to be addressed in cancer patients.
###end p 35
###begin p 36
###xml 227 235 <span type="species:ncbi:9606">patients</span>
In summary, we have shown that inter-individual variability in gene-body methylation is associated with repetitive elements and that it is possible to identify regions of significant differences between bilateral breast cancer patients and controls that may be useful as additional surrogate markers for breast cancer risk. This research also demonstrates the correlation between the level of gene-body methylation and mRNA level of a single gene and highlights the potential for gene-body epigenetic regulation of gene transcription. Finally, this work also supports the need to interrogate whole epigenomes, including repetitive elements, using tiling arrays or unbiased next-generation sequencing approaches to investigate the full complement of methylation variability across the genome.
###end p 36
###begin title 37
MATERIALS AND METHODS
###end title 37
###begin title 38
Clinical sample
###end title 38
###begin p 39
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C39">39</xref>
###xml 434 441 434 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C40">40</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C41">41</xref>
###xml 66 71 <span type="species:ncbi:9606">women</span>
###xml 885 893 <span type="species:ncbi:9606">patients</span>
###xml 1025 1033 <span type="species:ncbi:9606">patients</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
###xml 1233 1245 <span type="species:ncbi:9606">participants</span>
For the microarray analysis, peripheral blood DNA samples from 14 women with bilateral breast cancer were compared with the DNA samples from 14 age- and ethnicity-matched controls. The cases were selected by being (i) BRCA1 and BRCA2 mutation negative, confirmed clinically; (ii) metachronous tumours (separate sites) (iii) and those meet the bilateral case criteria set by Chaudary et al. (39), namely (a) subsequent tumour contains in situ component; (b) distinct histological types; (c) subsequent tumour has greater degree of differentiation; (d) no evidence of metastatic spread from ipsilateral tumour. These samples were collected with ethics approval from the Institute for Womens Health, Toronto, Canada. Peripheral blood DNA samples from a second set of 190 bilateral cases and 190 controls were obtained from the British Breast Cancer study (40,41). Bilateral breast cancer patients were ascertained through the English and Scottish cancer registries, controls were friends or non-blood relatives of breast cancer patients. Controls were age-matched to patients at the age at blood draw (within +/- 2 months) and all patients and controls were Caucasians resident in the UK. Written informed consent was obtained from all participants, and the study was approved by the South East Multicentre Research Ethics Committee.
###end p 39
###begin title 40
DNA methylation profiling using microarrays
###end title 40
###begin p 41
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 225 228 225 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 345 348 345 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFN</italic>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 451 454 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RARB</italic>
###xml 507 514 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD17B4</italic>
A custom oligonucleotide tiling array was designed to target the testable genomic regions (plus 100 kb flanking sequence) of genes, including breast cancer susceptibility genes BRCA1 (82 kb), BRCA2 (86 kb), CHEK2 (57 kb) and ATM (143 kb) along with other genes that are known to be commonly methylated in breast cancer, including ESR1 (296 kb), SFN (1.3 kb), CDKN2A (27 kb), TP53 (19 kb), GSTP1 (2.8 kb), CDH1 (96 kb), CDH13 (1169 kb), HIC1 (4.0 kb), PGR (92 kb), SFRP1 (47 kb), MLH1 (57 kb), RARB (97 kb), HSD17B4 (90 kb). Arrays were designed by and performed by Nimblegen Inc. Specified regions were from UCSC HG17 with overlapping 50mer probes every 21 bp excluding repeat masked regions, and the probe set was replicated four times on the chip and averaged data were used for analysis. In addition to the 17 targeted genes, we also captured 26 genes and 12 partial genes which were peripherally targeted in the flanking regions by these tiling arrays ().
###end p 41
###begin p 42
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C42">42</xref>
###xml 343 346 343 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hpa</italic>
###xml 350 353 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aci</italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hin</italic>
###xml 815 816 815 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C43">43</xref>
The general principle of these DNA methylation arrays consists of hybridization of the unmethylated fraction of genomic DNA to the microarray containing oligonucleotides that represent the genomic region of interest. We performed the enrichment as described previously (42). Briefly, we used a cocktail of three methylation-sensitive enzymes (HpaII, AciI and Hin6I) to digest individuals genomic DNA and used ligation-mediated PCR to amplify products which were cleaned using Qiagen PCR cleanup kit (Qiagen, Canada), labelled with either Cy3 or Cy5 dyes and co-hybridized in matched pairs to the custom array. Hybridization intensity correlates with the DNA methylation status at the genomic locus homologous to each oligonucleotide on the array. MA2C was used for normalization, peak detection (using a cut-off of P < 0.001) and generation of MATScores for each probe (43).
###end p 42
###begin title 43
Pyrosequencing
###end title 43
###begin p 44
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C44">44</xref>
###xml 1187 1189 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP033C13">13</xref>
DNA samples were bisulphite-converted using EZ-96 DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA) following the manufacturers protocol. Pyrosequencing of LINE1 elements was performed using the LINE1 assay (Biotage, Hertford, UK). All other pyrosequencing assays were designed using the PyroQ assay design software (primers in ). All pyrosequencing assays for repetitive elements included at least one primer in a unique sequence outside of the repeat and followed by a unique nested primer pair for some amplicons to ensure specific amplification. A common tag was placed on either the forward or the reverse primer (depending on the strand to be sequenced), and a common universal biotinylated primer was used for all reactions as described previously (44). PCR was performed as described previously and cycling conditions included denaturation at 95degreesC for 4 min, followed by 10 cycles of 94degreesC for 15 s, touchdown from 60-50degreesC (-1 degree/cycle) for 15 s and 72degreesC for 20 s, followed by a further 30 cycles at 50degreesC annealing temperature. The second PCR used 2 microl of a 1:10 dilution of the first PCR as template and the same cycling conditions (13). All products were confirmed to be single bands by agarose gel electrophoresis. Methylation values were calculated as an average of all CpG sites within each assay as determined by the Pyro Q-CpG Software (Biotage, Uppsala, Sweden).
###end p 44
###begin title 45
Blood cell fractionation
###end title 45
###begin p 46
###xml 258 261 <span type="species:ncbi:9685">cat</span>
###xml 446 449 <span type="species:ncbi:9685">cat</span>
###xml 479 482 <span type="species:ncbi:9685">cat</span>
###xml 517 520 <span type="species:ncbi:9685">cat</span>
Peripheral blood was collected from two healthy female donors with informed consent. PBMCs were isolated using a standard Ficoll-paque protocol, and blood cell fractions were isolated using antibody-coated magnetic microbeads and MACS MS separation columns (cat: 130-042-201) following the manufacturers protocol (Miltenyi Biotech, Surrey, UK). Briefly, 5-10 million PBMCs were incubated with each of the antibody-coated beads for B-cells (CD19, cat: 130-050-301), T-cells (CD2, cat: 130-091-114) or monocytes (CD14, cat: 130-050-201). Genomic DNA was extracted from whole PBMCs and each cell-specific population. Bisulphite conversion and pyrosequencing were performed as described.
###end p 46
###begin title 47
Cancer cell lines
###end title 47
###begin p 48
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
DNA was extracted from 62 cell lines from brain (n = 7), breast (n = 5), colon (n = 5), leukaemia (n = 5), lymphoma (n = 9), sarcoma (n = 15) and others (n = 16). A full list of cell line names is included in  Bisulphite conversion and pyrosequencing were performed as described.
###end p 48
###begin title 49
Quantitative RT-PCR
###end title 49
###begin p 50
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATM</italic>
###xml 385 386 381 382 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 662 667 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
Quantitative RT-PCR was performed for ATM using an Eppendorf Mastercycler with the following primer pairs: ATM_F (5'-tgctcatacagcaggccata-3') with ATM_R (5'-aaggctgaatgaaagggtaattc-3') and GAPDH_F (5'-ggagtcaacggatttggtcgta-3') with GAPDH_R (5'-ggcaacaatatccactttaccagagt-3'). The reaction mix contained 1x SYBR green master mix (Applied Biosystems, Foster City, CA, USA) and 0.5 microm of each forward and reverse primers in a volume of 30 microl. PCR cycling consisted of 95degreesC for 10 min, then 40 cycles of 95degreesC for 30 s, 60degreesC for 60 s, followed by a meltcurve analysis. Fold-change in expression was calculated by DeltaDeltaCt normalized to GAPDH for each sample and normalizing each of the cell lines to the cell line SKBR3.
###end p 50
###begin title 51
Statistical analysis
###end title 51
###begin p 52
###xml 743 744 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1139 1142 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 1142 1143 1140 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The majority of statistical analysis in this study was performed using various R packages as described earlier. The simulated peak distributions were determined by randomly placing single peaks across the same tiled region and calculating the distances to the real repetitive elements and repeating 10 000 times. Kolmogorov-Smirnov test was used to test the significance of the difference in distributions (ks.test). We used Wilcoxon signed rank test for the analysis of methylation percentages obtained by pyrosequencing (wilcox.test). We performed further analysis for ATM mvp2a to confirm the significance of this difference using 1000 randomized simulations of the test statistic (W, from the Wilcoxon rank sum test) to calculate the real P-value of the observed test statistic. We used either generalized linear model (glm) regression or logistic regression analysis (lm) for further analysis of ATM MVP2b to assess the associations with phenotypic data. Inter-quartile analysis was performed by calculating the quartiles from all of the data (quantile) and counting the number of cases or controls in each quartile. We then used the chi2 test (chisq.test), odds ratio (oddsratio) and Cochran-Armitage trend test (independence_test).
###end p 52
###begin title 53
SUPPLEMENTARY MATERIAL
###end title 53
###begin p 54
.
###end p 54
###begin title 55
FUNDING
###end title 55
###begin p 56
###xml 61 110 61 110 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Canadian Cancer Etiology Research Network (CCERN)</grant-sponsor>
###xml 157 201 157 201 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">University College London Hospital Charities</grant-sponsor>
###xml 241 256 241 256 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cellcentric Ltd</grant-sponsor>
###xml 264 282 264 282 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cancer Research UK</grant-sponsor>
###xml 329 347 329 347 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cancer Research UK</grant-sponsor>
###xml 352 394 352 394 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Breakthrough Breast Cancer Research Centre</grant-sponsor>
This work was funded in part by a pilot study grant from the Canadian Cancer Etiology Research Network (CCERN) to A.P., S.N. and J.M.F. and a grant from the University College London Hospital Charities to J.M.F. J.M.F. was funded in part by Cellcentric Ltd and by Cancer Research UK. The British Breast Cancer study is funded by Cancer Research UK and Breakthrough Breast Cancer Research Centre. We acknowledge NHS funding to the NIHR Biomedical Research Centre. Funding to pay the Open Access charge was provided by a grant from the University College London Hospital Charities.
###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
[Supplementary Data]
###end title 58
###begin title 59
ACKNOWLEDGEMENTS
###end title 59
###begin p 60
The authors would like to thank Dr Jon Mill for a critical review of the manuscript and Dr Matthew Trotter for additional bioinformatic assistance.
###end p 60
###begin p 61
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 61
###begin title 62
REFERENCES
###end title 62
###begin article-title 63
Cancer statistics, 2005
###end article-title 63
###begin article-title 64
A genome wide linkage search for breast cancer susceptibility genes
###end article-title 64
###begin article-title 65
A comparison of bilateral breast cancers in BRCA carriers
###end article-title 65
###begin article-title 66
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk
###end article-title 66
###begin article-title 67
Germline epimutation of MLH1 in individuals with multiple cancers
###end article-title 67
###begin article-title 68
Altered methylation patterns in cancer cell genomes: cause or consequence?
###end article-title 68
###begin article-title 69
Chromatin modifications and their function
###end article-title 69
###begin article-title 70
###xml 36 41 <span type="species:ncbi:9606">human</span>
The epigenetic progenitor origin of human cancer
###end article-title 70
###begin article-title 71
Inherited epigenetic variation-revisiting soft inheritance
###end article-title 71
###begin article-title 72
###xml 57 63 <span type="species:ncbi:9606">humans</span>
The case for transgenerational epigenetic inheritance in humans
###end article-title 72
###begin article-title 73
Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer
###end article-title 73
###begin article-title 74
Epigenetic reprogramming in mammalian development
###end article-title 74
###begin article-title 75
###xml 51 56 <span type="species:ncbi:9606">human</span>
Intra- and interindividual epigenetic variation in human germ cells
###end article-title 75
###begin article-title 76
Identification of novel high-frequency DNA methylation changes in breast cancer
###end article-title 76
###begin article-title 77
###xml 70 75 <span type="species:ncbi:9606">human</span>
An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs)
###end article-title 77
###begin article-title 78
A molecular map of mesenchymal tumors
###end article-title 78
###begin article-title 79
###xml 18 23 <span type="species:ncbi:9606">women</span>
The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies
###end article-title 79
###begin article-title 80
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 80
###begin article-title 81
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer
###end article-title 81
###begin article-title 82
Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers
###end article-title 82
###begin article-title 83
Gene body-specific methylation on the active X chromosome
###end article-title 83
###begin article-title 84
###xml 24 44 24 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Arabidopsis thaliana</italic>
###xml 24 44 <span type="species:ncbi:3702">Arabidopsis thaliana</span>
Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription
###end article-title 84
###begin article-title 85
DNA methylation landscapes: provocative insights from epigenomics
###end article-title 85
###begin article-title 86
An epigenetic role for noncoding RNAs and intragenic DNA methylation
###end article-title 86
###begin article-title 87
###xml 78 83 <span type="species:ncbi:9606">human</span>
Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters
###end article-title 87
###begin article-title 88
###xml 32 37 <span type="species:ncbi:9606">human</span>
The antisense transcriptomes of human cells
###end article-title 88
###begin article-title 89
Dominant negative ATM mutations in breast cancer families
###end article-title 89
###begin article-title 90
Incidence of cancer in 161 families affected by ataxia-telangiectasia
###end article-title 90
###begin article-title 91
Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation
###end article-title 91
###begin article-title 92
Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers
###end article-title 92
###begin article-title 93
The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase
###end article-title 93
###begin article-title 94
The ATM gene is a target for epigenetic silencing in locally advanced breast cancer
###end article-title 94
###begin article-title 95
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
###end article-title 95
###begin article-title 96
Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival
###end article-title 96
###begin article-title 97
Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors
###end article-title 97
###begin article-title 98
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
###end article-title 98
###begin article-title 99
Intra-individual change over time in DNA methylation with familial clustering
###end article-title 99
###begin article-title 100
Epigenetic differences arise during the lifetime of monozygotic twins
###end article-title 100
###begin article-title 101
###xml 31 36 <span type="species:ncbi:9606">women</span>
Breast parenchymal patterns in women with bilateral primary breast cancer
###end article-title 101
###begin article-title 102
Association of genetic variants at 8q24 with breast cancer risk
###end article-title 102
###begin article-title 103
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study
###end article-title 103
###begin article-title 104
Microarray-based DNA methylation profiling: technology and applications
###end article-title 104
###begin article-title 105
Model-based analysis of two-color arrays (MA2C)
###end article-title 105
###begin article-title 106
Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping
###end article-title 106

